Immunome (NASDAQ:IMNM) Sets New 1-Year Low After Earnings Miss

Immunome, Inc. (NASDAQ:IMNM)’s stock price reached a new 52-week low on Wednesday following a weaker than expected earnings announcement. The company traded as low as $8.30 and last traded at $8.46, with a volume of 23224 shares trading hands. The stock had previously closed at $8.36.

The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The business had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%.

Analyst Ratings Changes

A number of research firms have issued reports on IMNM. Lifesci Capital began coverage on shares of Immunome in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Thursday. Guggenheim decreased their price objective on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Stephens restated an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a research report on Thursday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $25.50.

Insider Activity

In related news, CEO Clay B. Siegall bought 150,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were purchased at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of large investors have recently modified their holdings of IMNM. BNP Paribas Financial Markets bought a new stake in Immunome during the fourth quarter worth about $70,000. KLP Kapitalforvaltning AS bought a new stake in Immunome during the fourth quarter worth about $75,000. AlphaQuest LLC boosted its stake in Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after acquiring an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after acquiring an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Immunome during the fourth quarter worth about $95,000. Institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

The firm’s 50 day moving average is $9.80 and its 200 day moving average is $11.62. The firm has a market cap of $690.87 million, a P/E ratio of -1.07 and a beta of 1.93.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.